Results 41 to 50 of about 84,228 (303)
Familial Pancreatic Ductal Adenocarcinoma [PDF]
The American Journal of Pathology, 2019 Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve ...
Kelly E, Diaz, Aimee L, Lucas
openaire +2 more sources
Pancreatic Ductal Adenocarcinoma [PDF]
The American Journal of Pathology, 2019 Pancreatic ductal adenocarcinoma represents the most common malignant tumor of the pancreas. Despite substantial research efforts and gradual diagnostic and therapeutic improvements, its prognosis remains dismal. In accordance with the current German, European, and US guidelines, this CME-article provides a comprehensive review of the disease.
E, Gallmeier, T M, Gress
openaire +3 more sources
Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing
Frontiers in Immunology, 2023 N-4 cytidine acetylation (ac4C) is an epitranscriptome modification catalyzed by N-acetyltransferase 10 (NAT10) and is essential for cellular mRNA stability, rRNA biosynthesis, cell proliferation, and epithelial-mesenchymal transition (EMT).
Dong Xu +5 more
doaj +1 more source
MicroRNAs in pancreatic ductal adenocarcinoma
World Journal of Gastroenterology, 2011 Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed.
Jong Y, Park +5 more
openaire +2 more sources
Macrophages and pancreatic ductal adenocarcinoma [PDF]
Cancer Letters, 2016 Monocytes and macrophages make up part of the innate immune system and provide one of the first defenses against variety of treats. Macrophages can also modulate the adaptive immune system. Efficient sensing and response to tissue environmental cues highlights the complexity and dynamic nature of macrophages and their plasticity.
Habtezion, Aida +2 more
openaire +4 more sources
Imaging for pancreatic ductal adenocarcinoma
Chinese Clinical Oncology, 2017 Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Natally, Horvat +4 more
openaire +2 more sources
Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma [PDF]
, 2021 Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal and aggressive malignancies with a 5-year survival rate less than 9%. Early detection is particularly difficult due to the lack of symptoms even in advanced stages.
Collins, H. +8 more
core +1 more source
Technology in Cancer Research & Treatment, 2020 Background: Pancreatic ductal adenocarcinoma is a common malignancy with high morbidity. MicroRNAs have been demonstrated to be critical posttranscriptional regulators in tumorigenesis.
Ya-Dong Wang MD +3 more
doaj +1 more source
Pancreatic resections for advanced M1-pancreatic carcinoma : the value of synchronous metastasectomy
, 2010 Background: For M1 pancreatic adenocarcinomas pancreatic resection is usually not indicated. However, in highly selected patients synchronous metastasectomy may be appropriate together with pancreatic resection when operative morbidity is low ...
Chromik, Ansgar Michael +11 more
core +1 more source
Biomarkers in pancreatic ductal adenocarcinoma
Clinical and Translational Oncology, 2017 Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego +4 more
openaire +3 more sources